Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chronic obstructive ...

The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic dermatitis, a category that is currently dominated by Sanofi and Regeneron ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an invasive form of the digestive pathogen E. coli. Sanofi recorded a $250 ...

Sanofi and J&J discontinued E.mbrace phase 3 study after the vaccine showed insufficient efficacy in preventing invasive E. coli disease. Sanofi recorded a $250M impairment charge, lowering Q4 ...

Twenty-two lenders including Citigroup Inc., Goldman Sachs Group Inc. and Morgan Stanley extended an upfront commitment to CD&R last year so the firm could buy part of Sanofi SA’s consumer arm ...

In June 2020, inebilizumab received its first global approval in the USA for the treatment ... with IgG4-Related Disease. .Rilzabrutinib: Sanofi Rilzabrutinib is an oral, reversible, covalent ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

An even more major news would be an FDA review, but the EMA is a good second place. In my last coverage, I noted how the company “started” an MAA (the European application for approval over ...

The poll showed Trump getting a 53% approval rating with 59% of people supporting his immigration moves. Also, 64% of people approved sending troops to the US-Mexico border. The big number ...